Evidence map›Paper›PMID 32102902›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2020

TCRs with Distinct Specificity Profiles Use Different Binding Modes to Engage an Identical Peptide-HLA Complex.

Charlotte H Coles, Rachel M Mulvaney, Sunir Malla, Andrew Walker, Kathrine J Smith, Angharad Lloyd, Kate L Lowe, Michelle L McCully, Ruth Martinez Hague, Milos Aleksic and 14 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 55 citations in OpenAlex.

  1. Technical review of artificial intelligence in TCR-T therapy.Journal of the National Cancer Center · 2026
    Review
  2. Ensembles ofbioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Molecular Insights into Tumor Immunogenicity.Current issues in molecular biology · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Defining and Studying B Cell Receptor and TCR Interactions.Journal of immunology (Baltimore, Md. : 1950) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 2 institutions in 1 country.

Charlotte H ColesImmunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.ORCID 0000-0003-4525-7144
Rachel M MulvaneyImmunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.
Sunir MallaImmunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.ORCID 0000-0002-5653-2271
Andrew WalkerImmunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.ORCID 0000-0003-4715-4325
Kathrine J SmithGlaxoSmithKline, Medicines Research Centre, Stevenage, Hertfordshire SG1 2NY, United Kingdom.
Angharad LloydImmunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.ORCID 0000-0003-4569-9276
Kate L LoweImmunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.
Michelle L McCullyImmunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.
Ruth Martinez HagueImmunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.
Milos AleksicImmunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.
Jane HarperImmunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.
Samantha J PastonImmunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.ORCID 0000-0003-1928-208X
Zoe DonnellanImmunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.
Fiona ChesterImmunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.
Katrin WiederholdImmunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.
Ross A RobinsonImmunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.
Andrew KnoxImmunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.ORCID 0000-0002-1073-2091
Andrea R StaceyImmunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.
Joseph DukesImmunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.
Emma BastonImmunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.
Sue GriffinGlaxoSmithKline, Medicines Research Centre, Stevenage, Hertfordshire SG1 2NY, United Kingdom.ORCID 0000-0002-8516-7787
Bent K JakobsenImmunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.
Annelise VuidepotImmunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.
Stephen HarperImmunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and Stephen.Harper@immunocore.com bent.jakobsen@immunocore.com.ORCID 0000-0002-6029-8668
Immunocore (United Kingdom) · GBGlaxoSmithKline (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The molecular rules driving TCR cross-reactivity are poorly understood and, consequently, it is unclear the extent to which TCRs targeting the same Ag recognize the same off-target peptides. We determined TCR-peptide-HLA crystal structures and, using a single-chain peptide-HLA phage library, we generated peptide specificity profiles for three newly identified human TCRs specific for the cancer testis Ag NY-ESO-1

Indexed as

Cell LineHistocompatibility AntigensHLA-A2 AntigenHumansPeptide LibraryPeptidesReceptors, Antigen, T-CellHistocompatibility AntigensHLA-A2 AntigenPeptide LibraryPeptidesReceptors, Antigen, T-Cell

Identifiers

PMID32102902
PMCPMC7086387
OpenAlexW2999528130

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.